Combining the data on costs and QALYs, Beard and colleagues concluded that partial replacement was clearly the most ...

Zimmer Biomet has received 510(k) clearance from the US Food and Drug Administration (FDA) for ROSA Knee with OptimiZe ...

Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among ...

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration ...

In a move that would make even the Six Million Dollar Man jealous, Rochester Regional Health has officially stepped into the ...

Zimmer Biomet (ZBH) could be a strong choice for your investment portfolio, due to its high cash yield, solid fundamentals, ...

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official ...

As Ambulatory Surgery Centers (ASCs) continue to experience growth and greater complexity, operational efficiency has become a defining factor in long-term viability. During a session at Becker’s 31st ...

Market, valued at approximately USD 1.99 billion in 2023, is poised for steady growth at a compound annual growth rate (CAGR) of 4.6% through the forecast period of 2024 to 2032. This growth reflects ...

New research from a randomized clinical trial provides the strongest long-term evidence yet comparing partial (PKR) and total ...

There’s a new advanced pain management for patients undergoing total knee replacement surgery, which delivers long-lasting, ...

Competing with companies including Stryker and J&J, Zimmer has moved to strengthen its position by developing an updated ...